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Benzodiazepine site agonists modulate the firing pattern
of neurons via GABAA receptors and by that influence the
activity of the network in which they participate and cause
appropriate changes in behaviour. Since the amygdala is
involved in regulating anxiety, it can be expected that
GABAA receptors located in this brain region contribute to
the anxiolytic effects of benzodiazepine site agonists. Here
we take advantage of an in vivo mouse model [1] in which
a Phe to Ile point mutation was introduced into the gene
coding for the GABAA receptor γ2 subunit. This γ2F77I
mutation, which was also flanked by loxP sites, affects
only the benzodiazepine binding site of the respective
receptors, and mice carrying this mutation no longer are
sensitive to certain benzodiazepine site agonists but are
otherwise normal. Here we aim to selectively replace the
"benzodiazepine insensitive" mutated γ2F77I subunit by
a GFP-labeled native one in the amygdala of γ2F77Ilox
mice by a stereotaxic injection of recombinant adeno-
associated viral (rAAV) vectors expressing Cre-recombi-
nase and GFP-labeled wild-type γ2 subunits. It has been
demonstrated previously that the replaced wild-type sub-
units combine with endogenous subunits to form com-
pletely assembled receptors with normal subcellular
distribution. Then only those amygdala neurons express-
ing the GFP-labeled wild-type γ2 subunits can be modu-
lated by a systemic application of these benzodiazepine
site agonists and any behavioural effects observed with
these drugs must have been generated via these neurons.
In this report we present a preliminary characterization of
the newly developed mouse model demonstrating the
correct expression of Cre-recombinase and GFP-labeled
wild-type γ2 subunits in amygdala neurons by immuno-
histochemical and in situ hybridization techniques.
Future experiments aim to characterize our model by
behavioural pharmacology in paradigms of anxiety.
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